April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Long-Term Safety and Efficacy of Intravitreal Bevacizumab (IVB) for Aggressive Posterior Retinopathy of Prematurity (AP-ROP)
Author Affiliations & Notes
  • Pankaj Malhotra
    Surgery, University of Illinois College of Medicine, Peoria, Peoria, IL
  • Kamal Kishore
    Surgery, University of Illinois College of Medicine, Peoria, Peoria, IL
  • Footnotes
    Commercial Relationships Pankaj Malhotra, None; Kamal Kishore, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 5900. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Pankaj Malhotra, Kamal Kishore; Long-Term Safety and Efficacy of Intravitreal Bevacizumab (IVB) for Aggressive Posterior Retinopathy of Prematurity (AP-ROP). Invest. Ophthalmol. Vis. Sci. 2014;55(13):5900.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To evaluate the long-term safety and efficacy of IVB for the treatment of APROP.

 
Methods
 

We conducted a retrospective chart review of 28 eyes of 15 consecutive premature infants with AP-ROP treated with 0.625 mg/0.025 mL IVB at a single institution from May 2010 through September 2012 by three retina specialists. Only infants with at least six months follow-up (FU) were included for further analysis. Injection was administered in the inferonasal (IN) quadrant 2 mm behind the limbus in 11 eyes, and 1 mm behind the limbus in the inferotemporal (IT) quadrant in 17 eyes. We studied complications of injections and late retinal detachments (RD), and sought to investigate predictive factors for RD with regard to gestational age (GA), chronological age (CA), birth weight (BW), postmenstrual age (PMA) at treatment, injection site, and stage of ROP. We also reviewed surgical interventions, including laser, vitrectomy and cataract surgery following initial IVB injection.

 
Results
 

PMA, GA, CA, BW and stage of ROP were not statistically significant between the RD and No RD groups (Table). Two eyes developed cataract and needed cataract surgery (both IN group). RD was diagnosed in 7 eyes (25%, 95% CI 12.7-43.4%, all in IN group) of 4 patients. Mean+/-SD PMA at diagnosis of RD was 61.5+/-14.47 (range 47-82) weeks, and RD was diagnosed after a mean of 25.5+/-14.1 (range 9.5-45) weeks after IVB. Four of 21 (19%, 95% CI 7.6-40%) eyes in No RD group received supplemental laser 4-9 weeks following IVB due to reactivation of ROP. In RD group, surgical repair was performed on 5 eyes, with successful anatomical reattachment in 4. Injection 2 mm in IN quadrant was more likely to result in RD (64%, 95% CI 35.4-84.8% v 0%, p=0.003 Fisher Exact test). No eye received repeat IVB.

 
Conclusions
 

We encountered considerably higher incidence of complications compared to those reported in the BEAT-ROP study. Posterior injection site in IN location was associated with increased risk of RD. Most RDs occurred after 54 weeks, the cutoff for follow-up in BEAT-ROP.

  
Keywords: 706 retinopathy of prematurity • 748 vascular endothelial growth factor • 697 retinal detachment  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×